Oxford Biomedica (LON:OXB) Shares Pass Above 200 Day Moving Average – Should You Sell?

Oxford Biomedica plc (LON:OXBGet Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 600.87 and traded as high as GBX 850. Oxford Biomedica shares last traded at GBX 831, with a volume of 471,700 shares changing hands.

Analysts Set New Price Targets

OXB has been the subject of several research analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 451 price objective on shares of Oxford Biomedica in a report on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of GBX 606.40.

Get Our Latest Report on Oxford Biomedica

Oxford Biomedica Price Performance

The firm has a 50-day simple moving average of GBX 694.93 and a 200-day simple moving average of GBX 600.87. The firm has a market capitalization of £1.00 billion, a PE ratio of -22.94 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

About Oxford Biomedica

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

Featured Stories

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.